Last reviewed: July 9, 2026

Last updated: July 9, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

This article is part of the PlexusDx Education Hub — science-backed guidance on GLP-1 medications, metabolic health, and precision weight management.

Individuals pursuing in vitro fertilization while managing weight face a complex decision: whether GLP-1 receptor agonist medications like semaglutide can be used safely alongside fertility treatment. Current medical evidence suggests timing and careful monitoring matter significantly, and many reproductive specialists recommend pausing GLP-1 therapy before and during IVF cycles, though individual circumstances vary based on metabolic health, BMI, and treatment goals.

GLP-1 Medications and Reproductive Health: What the Evidence Shows

GLP-1 receptor agonists—including semaglutide and tirzepatide—work by slowing gastric emptying and signaling fullness to the brain, leading to reduced calorie intake and weight loss. These medications were originally developed for type 2 diabetes management but have gained attention for their metabolic benefits in weight management. However, pregnancy safety data for GLP-1 drugs remains limited, with most animal studies showing no direct fetal harm, yet human clinical trials in pregnant individuals are still ongoing.

The American College of Obstetricians and Gynecologists (ACOG) and major fertility societies have not issued blanket prohibitions on GLP-1 use during fertility treatment, but many reproductive endocrinologists recommend stopping these medications before ovulation stimulation begins. The primary concern is not established teratogenicity but rather the lack of sufficient safety data during the critical window of egg maturation, embryo development, and early pregnancy. Weight loss itself during active IVF cycles may theoretically affect hormone production and egg quality, making medical supervision essential.

Why Timing Matters: GLP-1 Use Before, During, and After IVF

Most fertility specialists recommend a washout period of 4-8 weeks before beginning ovulation induction, allowing GLP-1 medications to clear from your system and your metabolic state to stabilize. This timing allows your body to establish consistent hormone levels—critical for successful egg retrieval and fertilization. If you've been taking semaglutide or another GLP-1 medication, discuss the exact timing with your reproductive endocrinologist, who can coordinate with your primary care provider to create a safe treatment transition plan.

During the IVF cycle itself—from ovulation stimulation through embryo transfer—most fertility centers recommend avoiding new GLP-1 initiation. After successful embryo transfer and during pregnancy, GLP-1 medications are typically discontinued until more robust pregnancy outcome data becomes available. However, post-IVF weight management remains important; some specialists support resuming GLP-1 therapy after pregnancy completion, depending on breastfeeding plans and individual health factors. PlexusDx works with patients who need flexible, personalized medication timelines coordinated with fertility care.

Weight Management and Fertility: The Metabolic Connection

Body weight significantly influences fertility outcomes, with research showing that both excess weight and rapid weight loss can affect ovulation, egg quality, and implantation success. A BMI above 30 is associated with reduced IVF success rates, increased miscarriage risk, and complications during pregnancy; however, weight loss of 5-10% before fertility treatment can improve outcomes. The challenge for many individuals is achieving meaningful weight reduction without destabilizing hormones or affecting egg quality during the critical preparation phase before IVF.

Personalized approaches that address underlying metabolic factors—rather than one-size-fits-all calorie restriction—may support both fertility and sustainable weight management. PlexusDx offers the Precision Peptide Genetic Test, which identifies individual variations in GLP1R, GIPR, FTO, and MC4R pathways, revealing why certain weight management strategies work better for specific genetic profiles. This data can inform whether you're a strong candidate for GLP-1 therapy before your fertility window, or whether alternative metabolic support might be appropriate during your IVF preparation phase.

PlexusDx Personalized Semaglutide and Fertility Planning

PlexusDx provides compounded semaglutide injection starting at $189/mo (or $149/mo on the 6-month plan) from licensed 503A compounding pharmacies, with no insurance required and HSA/FSA eligibility available. If you're planning IVF within 3-12 months and weight management is a priority, working with a PlexusDx-affiliated provider can help establish your baseline metabolic profile, optimize weight before your fertility treatment window, and then coordinate medication pauses with your reproductive endocrinologist. Your dose may need to go up. Your price won't.—PlexusDx pricing remains flat across all three commitment tiers, removing cost uncertainty from your treatment plan.

Before starting semaglutide alongside IVF planning, schedule a coordinated consultation with both your fertility specialist and your primary care physician to review timing, dosing, and individual risk factors. The Precision Peptide Genetic Test ($99 add-on after your first month) reveals how your unique genetic variants influence GLP-1 responsiveness and metabolic pathways, informing whether semaglutide is an optimal fit for your fertility-weight management timeline. PlexusDx serves all 50 states and coordinates care transparently, ensuring your fertility goals and metabolic health move forward together.

How Your Genetics Relate to GLP-1 Pathways

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — relate to the biological pathways these medications act on. These are pathway-level associations only and do not predict how much weight you will lose or how you will respond to any specific medication. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights so you and your provider can see how your genes relate to these pathways. It does not recommend, prescribe, or determine which medication, dose, or peptide is right for you. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month of treatment) gives you and your provider pathway-level genetic context to support a more personalized conversation. Genetics is a guide, not a guarantee.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Injection starts at $189/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.

Frequently Asked Questions

Is it safe to take semaglutide during IVF egg retrieval?

Most reproductive endocrinologists recommend pausing GLP-1 medications like semaglutide 4-8 weeks before ovulation stimulation begins. While no direct fetal harm has been documented, human pregnancy safety data remains limited, and stopping these medications before the critical egg maturation window protects both egg quality and early embryo development. Always coordinate timing with your fertility specialist.

Can weight loss from GLP-1 therapy improve my IVF success rates?

Yes—a 5-10% weight reduction before IVF is associated with better egg quality, higher fertilization rates, and improved implantation success, especially for individuals with a BMI above 30. However, this weight loss should occur before your fertility treatment cycle begins, not during it. Strategic use of semaglutide 2-3 months before IVF preparation can support metabolic readiness without interfering with hormone stimulation.

How much does personalized GLP-1 therapy cost at PlexusDx?

Compounded semaglutide injection starts at $189/mo (or $149/mo on the 6-month plan) across all three commitment tiers, with no insurance requirement or membership fees. HSA and FSA accounts are eligible. The optional Precision Peptide Genetic Test costs $99 as an add-on after your first month, revealing your unique metabolic and GLP-1 pathway profile to optimize your fertility-weight management plan.

What happens to weight after I stop semaglutide for IVF?

No — the Precision Peptide Genetic Test does not predict your response to semaglutide or any specific medication. It analyzes pathway-level variants (GLP1R, GIPR, FTO, and MC4R) that relate to the biology involved, offering context for a conversation with your provider rather than a prediction.

Can the PlexusDx genetic test help me plan my fertility and weight management timeline?

No — the Precision Peptide Genetic Test does not predict your response to semaglutide or any specific medication. It analyzes pathway-level variants (GLP1R, and GIPR) that relate to the biology involved, offering context for a conversation with your provider rather than a prediction.

Related Reading

Pricing and availability current as of July 2026. Compounded GLP-1 medications are not FDA-approved drug products; they are prepared by licensed compounding pharmacies under federal compounding regulations. Compounded semaglutide and tirzepatide are not the same as Wegovy, Ozempic, Zepbound, or Mounjaro. This article is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting, stopping, or changing any medication.

Return to the PlexusDx Education Hub for more evidence-based resources on GLP-1 therapy, metabolic health, and personalized weight management.

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.

Real prescribers. Published prices. No surprises.

Licensed providers in all 50 states. Online intake. No insurance, no membership required.

Start My Intake →

~60 seconds · $0 charged until your provider approves